There’s never enough time to fully track asbestos developments in Europe. However, a December 2018 article from Clyde & Co, caught my eye and is worth reading as to the assessment of defense side lawyer regarding the evidence needed for a plaintiff to prevail on secondary exposure cases, and trial practice in Scotland. The conclusions

At long last, plans are moving forward to establish a national mesothelioma patient registry in the United States. A key meeting of experts planning the registry will be held on Tuesday March 26, 2019  in Bethesda. The meeting will include panel presentations by mesothelioma experts from CDC and NIOSH, and will include a substantial opportunity

In the UK, an “overalls” case is a shorthand term for a “take home” case, as we refer to them in the US. Of greater note, a UK plaintiff recently succeeded  in such a case, as described in a February 18, 2019 post at AsbestosLaw blog, which is published by UK Barristers who acted

Interesting times ahead as Imerys filed a chapter 11 petition in an effort to try to manage the mesothelioma and ovarian cancer claims against it and other entities.  The petition and a related declaration list the top 30 plaintiff firms, which includes numerous plaintiff firms that are not “regulars” in chapter 11 asbestos cases, as

My automated daily google search for “asbestos” recently pulled up a link to a 90 minute video, apparently from the Library of Congress. The landing page is: https://lccn.loc.gov/91790914/dc

The page includes both the video, and the following information:

“About this Item

Title
The story of asbestos–illustrating the mines and factories of the H.W. Johns-Manville Company

It’s good to see more lawyers focused on genomics as related to causation in mass tort cases. A group from Goldberg Segalla just wrote about the topic as part of a broader paper on alternative causation issues. The article was published in Mealey’s Asbestos; it is: Defense Strategies For Alternative Causation Arguments In Asbestos Case,

Some scientific findings provide both opportunities and risks for litigants in mass tort cases. The point is highlighted by a new paper by Panou and colleagues published in mid- August in the Journal of Clinical Oncology. The paper concludes that a significant proportion (12%) of patients with malignant mesotheliomas carry inherited (germline) mutations in